Registration and abstract submissions now open for the EASO COMs Summit 2026 Registration and abstract submissions now open for the EASO COMs Summit 2026 COMs, Education, Upcoming Events
Meet the 2026 EASO – Novo Nordisk Foundation Award Winners Meet the 2026 EASO – Novo Nordisk Foundation Award Winners Awards, Early Career Network, ECN, Research
Enrichment of health-associated gut bacteria after a short-term dietary intervention in elderly obese subjects Enrichment of health-associated gut bacteria after a short-term dietary intervention in elderly obese subjects ECO
Food marketing in the digital age – immersive, influential, unstoppable Food marketing in the digital age – immersive, influential, unstoppable ECO
Patient Council Teaching Course On Stigma & Bias Patient Council Teaching Course On Stigma & Bias Patient Council
Nutrition Working Group-EFAD Evidence and Efficacy Nutrition Working Group-EFAD Evidence and Efficacy ECO
What is the current state of childhood obesity management What is the current state of childhood obesity management ECO
Early achievement of significant weight loss with naltrexone-bupropion is associated with additional weight loss and improved glycemic control at 1 year in patients with type 2 diabetes Early achievement of significant weight loss with naltrexone-bupropion is associated with additional weight loss and improved glycemic control at 1 year in patients with type 2 diabetes ECO
Integrating obesity research from across the globe Integrating obesity research from across the globe ECO
Third Expert Report on diet, nutrition, physical activity and cancer Third Expert Report on diet, nutrition, physical activity and cancer ECO
Creating Bariatric Friendly Spaces and Places to Improve Health Outcomes Creating Bariatric Friendly Spaces and Places to Improve Health Outcomes ECO
Changing the Public Health Narrative about Obesity Changing the Public Health Narrative about Obesity ECO
Behavioural therapy, lessons from the US and Europe Behavioural therapy, lessons from the US and Europe ECO
A Randomised, Phase 2, Placebo- and Active-Controlled Dose-Ranging Study of Semaglutide For Treatment of Obesity in Subjects Without Diabetes A Randomised, Phase 2, Placebo- and Active-Controlled Dose-Ranging Study of Semaglutide For Treatment of Obesity in Subjects Without Diabetes ECO
